Related scientific articles (all)

Single-access laparoscopic primary and incisional prosthetic hernia repair: first 50 patients.

Authors : Dapri G, Bruyns J, Paesmans M, Himpens J, Cadière GB
Year : 2013
Journal : Hernia
Volume : 17(5)
Pages : 619-26

18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO.

Authors : Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, de Azambuja E, Fauria K, van Dooren V, Aktan G, Coccia-Portugal MA, Kim SB, Vuylsteke P, Cure H, Eidtmann H, Baselga J, Piccart-Gebhart M, Flamen P, Di Cosimo S
Year : 2013
Journal : J. Nucl. Med.
Volume : 54(11)
Pages : 1862-8

Genomic grade adds prognostic value in invasive lobular carcinoma.

Authors : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Sandy H, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : Ann Oncol
Volume : 24(2)
Pages : 377-84

Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: A randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

Authors : Ribrag V, Tilly H, Casasnovas O, Bosly A, Bouabdallah R, Delarue R, Boue F, Bron D, Feugier P, Haioun C, Offner F, Coiffier B
Year : 2013
Journal : Eur. J. Cancer
Volume : 49(4)
Pages : 904-910

An atypical presentation of bronchial adenocarcinoma.

Authors : Langouo Fontsa M, CsToth I, Berghmans T, Feoli F, Meert AP
Year : 2013
Journal : Rev Med Brux
Volume : 34(3)
Pages : 181-3

CD4+ follicular helper T cell infiltration predicts breast cancer survival.

Authors : Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothé F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart-Gebhart M, Sotiriou C, Willard-Gallo K
Year : 2013
Journal : J Clin Invest
Volume : 123(7)
Pages : 2873-92

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.

Authors : Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart-Gebhart M
Year : 2013
Journal : Eur. J. Cancer
Volume : 49(12)
Pages : 2621-32

Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia.

Authors : Fayyad-Kazan H, Bitar N, Najar M, Lewalle P, Fayyad-Kazan M, Badran R, Hamade E, Daher A, Hussein N, Eldirani R, Berri F, Vanhamme L, Burny A, Martiat P, Rouas R, Badran B
Year : 2013
Journal : J Transl Med
Volume : 11(1)
Pages : 31

Clinical practice-changing trials: the HERA study paradigm.

Authors : Zardavas D, Ades F, de Azambuja E
Year : 2013
Journal : Expert Rev Anticancer Ther
Volume : 13(11)
Pages : 1249-56

Optimizing taxane use in MBC in the emerging era of targeted chemotherapy.

Authors : Von Minckwitz G, Martin M, Wilson G, Alba E, Schmidt M, Biganzoli L, Awada A
Year : 2013
Journal : Crit Rev Oncol Hematol
Volume : 85(3)
Pages : 315-31

Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP).

Authors : Ades F, de Azambuja E, Daugaard G, Ameye L, Moulin C, Paesmans M, De Jong D, Decoster L, De Greve J, Ismael G, Møller AK, Piccart-Gebhart M, Awada A
Year : 2013
Journal : J Chemother
Volume : 25(4)
Pages : 239-46

Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer.

Authors : Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pêgo A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, Melezínková H, Awada A
Year : 2013
Journal : J. Clin. Oncol.
Volume : 31(20)
Pages : 2586-92

Personalised cancer management: closer, but not here yet.

Authors : Piccart-Gebhart M
Year : 2013
Journal : Ann Oncol
Volume : 24(8)
Pages : 1951-5

Intrathecal Trastuzumab Treatment of the Neoplastic Meningitis due to Breast Cancer: A Case Report and Review of the Literature.

Authors : Dumitrescu C, Lossignol D
Year : 2013
Journal : Case Rep Oncol Med
Volume : 2013
Pages : 154674

Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states.

Authors : Ades F, Senterre C, de Azambuja E, Sullivan R, Popescu R, Parent F, Piccart-Gebhart M
Year : 2013
Journal : Ann Oncol
Volume : 24(11)
Pages : 2897-902

An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

Authors : Schöffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Gelderblom H, Willey R, Grebennik DO
Year : 2013
Journal : Eur. J. Cancer
Volume : 49(15)
Pages : 3219-28

Performance and abnormal cell flagging comparisons of three automated blood cell counters: Cell-Dyn Sapphire, DxH-800, and XN-2000.

Authors : Hotton J, Broothaers J, Swaelens C, Cantinieaux B
Year : 2013
Journal : Am J. Clin. Pathol.
Volume : 140(6)
Pages : 845-52

Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles.

Authors : Aftimos P, Wiedig M, Langouo Fontsa M, Awada A, Ghanem G, Journe F
Year : 2013
Journal : Int J Oncol
Volume : 43(3)
Pages : 919-26

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

Authors : Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart-Gebhart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS
Year : 2013
Journal : Adv Ther
Volume : 30(10)
Pages : 870-84

Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.

Authors : Oakman C, Francis PA, Crown J, Quinaux E, Buyse M, de Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Jakesz R, Thürlimann B, Gutiérrez J, Harvey V, Punzalan L, Dell orto P, Larsimont D, Steinberg I, Gelber Rd, Piccart-Gebhart M, Viale G, Di Leo A
Year : 2013
Journal : Ann Oncol
Volume : 24(5)
Pages : 1203-11